Analysts’ Top Healthcare Picks: Masimo Corp (MASI), Rhythm Pharmaceuticals Inc (RYTM)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Masimo Corp (MASIResearch Report) and Rhythm Pharmaceuticals Inc (RYTMResearch Report) with bullish sentiments.

Masimo Corp (MASI)

Needham analyst Michael Matson maintained a Buy rating on Masimo Corp today and set a price target of $155. The company’s shares opened today at $136.22, close to its 52-week high of $141.05.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 12.2% and a 66.8% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Masimo Corp is a Strong Buy with an average price target of $145.50.

See today’s analyst top recommended stocks >>

Rhythm Pharmaceuticals Inc (RYTM)

In a report released today, Alan Carr from Needham maintained a Buy rating on Rhythm Pharmaceuticals Inc, with a price target of $42. The company’s shares opened today at $28.03.

According to TipRanks.com, Carr is a 4-star analyst with an average return of 6.2% and a 46.7% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Lexicon Pharmaceuticals.

Currently, the analyst consensus on Rhythm Pharmaceuticals Inc is a Strong Buy with an average price target of $39.75.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.